Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BHQ880 + zoledronic acid
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**BHQ880 + zoledronic acid** is a combination therapy used in clinical studies for the management of multiple myeloma-related bone disease. BHQ880 is a humanized monoclonal antibody that neutralizes Dickkopf-1 (DKK1), a protein overexpressed in myeloma cells and known to suppress osteoblast function, thereby contributing to bone disease. By blocking DKK1, BHQ880 aims to stimulate bone formation and may have anti-myeloma activity. **Zoledronic acid** is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and disrupting osteoclast function. The combination is delivered intravenously and targets both the prevention of bone loss (zoledronic acid) and active bone regeneration (BHQ880), with the added potential to reduce myeloma burden.
- Other names
- zoledronate
02
Targets
FDPS (Farnesyl pyrophosphate synthase)DKK1 (Dickkopf-related protein 1)
Beyond the preview
Go deeper on BHQ880 + zoledronic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BHQ880 + zoledronic acid.